{"id":127,"date":"2025-05-30T22:00:00","date_gmt":"2025-05-30T22:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=127"},"modified":"2025-09-01T13:49:00","modified_gmt":"2025-09-01T13:49:00","slug":"china-bd-2025-evopoint-and-astellas-enters-a-1-54-billion-usd-license-on-cldn18-2-adc-xnw27011","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/127.html","title":{"rendered":"[China BD 2025] Evopoint and Astellas enters a 1.54 billion USD license on CLDN18.2 ADC XNW27011"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><\/h2>\n\n\n\n<p>Announced Date: 2025-05-29 (May 29, 2025)<\/p>\n\n\n\n<p>Asset Name: XNW27011<\/p>\n\n\n\n<p>Licensor: Evopoint (Evopoint Biosciences\u00a0Co., Ltd., China)<\/p>\n\n\n\n<p>Licensee (Buyer): Astellas (Astellas\u00a0Pharma\u00a0Inc., Japan)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: ADC (antibody drug conjugate)&nbsp;<\/p>\n\n\n\n<p>Asset Target: CLDN18.2<\/p>\n\n\n\n<p>Potential Indication: solid tumors, including gastric cancer, gastroesophageal cancer and pancreatic cancer<\/p>\n\n\n\n<p>Current Stage: Phase I\/II, in China<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority: &nbsp;<\/p>\n\n\n\n<p>Evopoint has granted Astellas exclusive worldwide rights (excluding\u00a0China&#8217;s\u00a0mainland,\u00a0Hong Kong,\u00a0Macao\u00a0and\u00a0Taiwan\u00a0region) to develop and commercialize XNW27011\u00a0.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of $130 million,<\/p>\n\n\n\n<p>Near-term payment  up to $70 million,<\/p>\n\n\n\n<p>Milestone payments up to \u00a0$1.34 billion.<\/p>\n\n\n\n<p>Tiered royalties on net sales.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/newsroom.astellas.us\/2025-05-29-Astellas-Enters-Exclusive-License-Agreement-with-Evopoint-Biosciences-for-XNW27011,-a-Novel-Clinical-stage-Antibody-Drug-Conjugate-Targeting-CLDN18-2\">Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2 &#8211; May 29, 2025<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-05-29 (May 29, 2025) Asset Name: XNW27011 Licensor: Evopoint (Evopoint Biosciences\u00a0Co., Ltd., China) Licensee &hellip; <a title=\"[China BD 2025] Evopoint and Astellas enters a 1.54 billion USD license on CLDN18.2 ADC XNW27011\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/127.html\"><span class=\"screen-reader-text\">[China BD 2025] Evopoint and Astellas enters a 1.54 billion USD license on CLDN18.2 ADC XNW27011<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-127","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=127"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/127\/revisions"}],"predecessor-version":[{"id":128,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/127\/revisions\/128"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}